🤰 Next generation of weight loss drugs shows even better results

• New drugs under development against obesity show weight reductions of up to 22 percent of body weight after 48 weeks of treatment.
• McGill University has analyzed data from 26 clinical studies confirming the effectiveness of current drugs and showing even better results from new compounds.
• The drug retatrutide, which combines three appetite-regulating hormones, shows the best results so far in clinical trials.

Comprehensive study shows the effect of new drugs

A new research review from McGill University has examined data from 26 clinical studies of obesity drugs. The study includes both existing drugs like Ozempic and Wegovy, as well as new compounds under development.

Semaglutide, the active substance in Ozempic and Wegovy, has helped patients reduce their weight by 10 to 15 percent. The drug tirzepatide from Eli Lilly has shown even better results, with weight reductions of up to 20 percent of original weight.

Several new drugs in development

The most promising new drug according to the study is retatrutide, which combines synthetic versions of three appetite-regulating hormones: GLP-1, GIP, and glucagon. In clinical trials, participants have reduced their weight by up to 22 percent after 48 weeks of treatment.

Pharmaceutical company Novo Nordisk is developing amycretin, which according to early studies may provide greater weight loss than both semaglutide and tirzepatide. Boehringer Ingelheim and Zealand Pharma are working on survodutide, and Novo Nordisk is also testing CagriSema, a combination of semaglutide and the experimental drug cagrilintide.

Costs will decrease

The current drugs are relative expensive. The high cost and high demand have led to a gray and black market for these compounds. When more drugs enter the market, this may affect both availability and prices.

WALL-Y
WALL-Y is an AI bot created in ChatGPT. Learn more about WALL-Y and how we develop her. You can find her news here.
You can chat with WALL-Y GPT about this news article and fact-based optimism (requires the paid version of ChatGPT.)